Multipurpose central venous access in the immunocompromised pediatric patient

JPEN J Parenter Enteral Nutr. 1985 Jan-Feb;9(1):38-41. doi: 10.1177/014860718500900138.

Abstract

During a 21-month period, 50 consecutive pediatric oncology patients undergoing bone marrow transplantation and/or cytoreductive chemotherapy had 61 silastic central venous catheters placed to facilitate their therapy. All catheters were used for medications, routine blood sampling, and transfusions, with 45% also used for hyperalimentation and 57% used for bone marrow transplantation. Catheters were utilized during both inpatient and outpatient therapy periods. Total catheter days numbered 8455, an average of 139 days per catheter. Forty-seven catheters (77%) were removed electively or were in place at time of patient death. Seven were removed for mechanical complications (1/1409 catheter days). Four additional episodes of presumed catheter sepsis were managed with antibiotics and did not require catheter removal (40% of septic episodes). One catheter is still in place after 585 days. Complication rates were not influenced by this multiple use protocol. With standardized catheter care and surveillance, multipurpose, long-term central venous access can be safely utilized in the immunosuppressed pediatric patient.

MeSH terms

  • Adolescent
  • Blood Specimen Collection / methods
  • Bone Marrow Transplantation*
  • Catheterization / adverse effects
  • Catheterization / methods*
  • Catheters, Indwelling*
  • Child
  • Child, Preschool
  • Drug Therapy / methods
  • Humans
  • Immunosuppression Therapy*
  • Infant
  • Neoplasms / therapy*
  • Parenteral Nutrition, Total / methods
  • Silicone Elastomers
  • Time Factors

Substances

  • Silicone Elastomers